Botulism refers to an acute illness which can prove to be lethal if not treated on time, and it is caused by the neurotoxins released by the bacterium C. botulinum. We take pride in steering ongoing progress towards the pursuit of effective therapies against botulism as well as the development of vaccines against the disease, with all our efforts taking the form of our patented service as vaccine developers and therapy providers.
Overview of Botulism
Botulism is defined as a rare disease and medical condition caused by the consumption of neurotoxins produced by Clostridium botulinum bacteria, BoNT. BoNTs are considered to be some of the most powerful and lethal toxins, infamously known to cause muscle weakness, paralysis, and in extreme cases, cessation of breathing. There are three types of transmission methods through which botulism can spread; foodborne, wound and infant botulism.
Fig. 1 Endopep-MS method in Botulism diagnostics. (Centurioni D. A., et al., 2022)
Vaccine Development for Botulism
Conventional Vaccine Approaches
In the past, vaccines were generated through injecting damaged viruses or even multiple weak forms of the same toxin. It does, however, possess considerable drawbacks such as requiring thorough examination of its possible side effects.
Synthetic Peptide Vaccines
In their research, Atassi and his group have managed to create peptides which cross over each other and occupy the entire HC area of BoNT/A. Such analyzed peptides were able to stimulate antigenically active mice in antibody as well as T-cell response which could perhaps one day be the basis for the creation of a synthetic vaccine to counteract the effects of BoNT poisoning.
Recombinant Vaccines
In a various studies the mice, are shown to be vaccinated with some non nontoxic fragments and such fragments are proven potent against protective immunity. This was performed by taking the Escherichia coli and by subcloning the portions of BoNTA gene. Usual Carboxy-fragment C-nitro toxin arm has been of great interest as it has proved to give complete protection when displayed in the mouse model.
Mutated Holotoxin Approach
Such a method seeks to eliminate the endoproteolitic function of the light chain through the change of definite amino acid residues. Although this method preserves binding and internalization activities which can be a safety concern, a lot of testing and assessment must be done to guarantee the safety and efficacy of the vaccine.
Therapeutics Development for Botulism
The administration of botulinum antitoxin is an essential part for the treatment of botulism .Botulinum antitoxin Crosses through blood and nullifies the effect of the botulinum toxin by passive immunization. It helps in disease progression by preventing additional binding of the toxin at the neuromuscular junctions. In adults, a trivalent antitoxin that contains neutralizing antibodies against botulinum toxin type A, B and E is usually used. In addition, a heptavalent antitoxin against botulism which was developed, and approved by the US FDA in 2013, prevents all known strains of botulism.
Should you be interested in botulism therapy development in a more complete manner, Our company can help you. To find out how we can help you to this end please follow the link below.
Our Services
We are proud to state that our firm is among the leading companies in the development of botulism drugs and botulism therapies, putting into action new methods and utilizing modern technologies to offer end-to-end solutions.
Infectious Disease Models
- Running Wheel Mouse Models
- Sublethal Dose of BoNT-induced Rabbit Models
- Infant Botulism Rat Models
- Customized Animal Models
Preclinical Research
- Drug Safety Evaluation
- In Vivo Pharmacokinetics Study
- In Vitro Pharmacokinetics Study
- Activity Testing
- Drug Resistance Evaluation
We continue our Botulinum therapy and vaccine development work through offering high quality preclinical services. Our qualified and multidisciplinary team does all sorts of testing, including but not limited to toxicity, immunogenicity and efficacy of the vaccines developed. Should our proposal be of any interest to you, please do not hesitate to contact us for more details and for a customized quotation of the services that you need.
References
- Centurioni Dominick A., Christina T. Egan, and Michael J. Perry. "Current developments in diagnostic assays for laboratory confirmation and investigation of botulism." Journal of Clinical Microbiology 60.4 (2022): e00139-20.
- Przedpel ski Amanda, et al. "Enhancing toxin-based vaccines against botulism." Vaccine 36.6 (2018): 827-832.
All of our services and products are intended for preclinical research use
only and cannot be used to diagnose, treat or manage patients.
